Tekmira Pharmaceuticals Corp. plans to change its corporate name to Arbutus Biopharma Corp., a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before August 3, 2015.
The combined entity currently fields the largest portfolio of HBV product candidates in the industry and is led by an experienced and proven leadership team shown below with notable prior experience, the company says.
"We are very excited about the prospects for our integrated new company, which has undergone a transformation to a complete HBV solutions company," said Dr. Mark J. Murray, president and CEO of Tekmira. "The company possesses exceptionally strong and proven clinical development, scientific and commercial leadership teams and is very well resourced to execute against our goal of delivering a cure for chronic HBV. We believe that the market opportunity for a curative regimen for HBV is very significant, likely eclipsing the HCV market, and presents a meaningful opportunity for shareholders."
Read the full release